Key Highlights
• CVSA shares surged approximately 13.46 percent to $140.98, a gain of $16.72 from a prior close of $124.26.
• Fiscal fourth quarter adjusted EPS of $2.09 beat the $1.89 expected, with revenue of $501.4 million topping the $494.9 million estimate.
• The company issued fiscal 2027 guidance for revenue between $2.05 billion and $2.09 billion, both above and slightly above analyst estimates.
• The company returned $238 million to shareholders via buybacks, while issuing fiscal 2027 guidance for continued growth.
Fiscal Q4 Beat Across Metrics
Covista Inc. (NYSE:CVSA), formerly Adtalem Global Education Inc., America's largest healthcare educator serving over 100,000 students across accredited institutions including Chamberlain, Ross University, and Walden University, closed up 13.46 percent at $140.98 after fiscal fourth quarter results beat estimates, with adjusted EPS of $2.09 versus $1.89 expected and revenue of $501.4 million topping the $494.9 million estimate. The company also reported full-year adjusted EPS of $8.30 and revenue growth gains.
Both Walden and Chamberlain segments contributed to the beat, with enrollment growth and record enrollments at both institutions cited as key drivers of the quarter's results.
Fiscal 2027 Guidance
Fiscal 2027 guidance initiated: revenue expected in the range of $2.05 billion to $2.09 billion, growth of 5 to 8 percent, and adjusted EPS expected in the range of $8.90 to $9.35, an 8 to 11 percent growth range, with more improvement expected in the back half of the year.
Strong balance sheet and capital returns highlighted, with full year operating cash flow of $471 million (up 41 percent), free cash flow of $393 million (up 39 percent), net leverage improved to 0.5x, and $238 million returned to shareholders via share repurchases in fiscal 2026, with $662 million remaining under the $750 million repurchase program.
Conclusion
In summary, Covista (NYSE:CVSA) shares rose approximately 13.46 percent to $140.98 at last closing, driven by a fiscal fourth quarter beat and fiscal 2027 guidance topping analyst expectations. These are the verified facts from the earnings release and market data. Whether the rally proves durable may depend on continued enrollment growth at Walden and Chamberlain and progress on the company's capital return program.





_11_20_2026_12_38_15_908731.jpg)
Please wait processing your request...